- Report
- November 2022
- 154 Pages
Global
From €4551EUR$5,000USD£3,901GBP
- Report
- December 2019
- 59 Pages
Global
From €3640EUR$4,000USD£3,121GBP
- Report
- September 2021
- 258 Pages
Global
From €2503EUR$2,750USD£2,146GBP
€5006EUR$5,500USD£4,291GBP
- Report
- December 2023
- 220 Pages
Global
From €3003EUR$3,300USD£2,575GBP
- Report
- October 2023
- 420 Pages
Global
From €2639EUR$2,900USD£2,263GBP
- Report
- June 2022
- 1500 Pages
Global
From €3549EUR$3,900USD£3,043GBP
- Drug Pipelines
- May 2022
- 400 Pages
Global
From €2730EUR$3,000USD£2,341GBP
- Report
- November 2021
- 222 Pages
Global
From €2730EUR$3,000USD£2,341GBP
- Report
- December 2021
- 353 Pages
Global
From €2503EUR$2,750USD£2,146GBP
€5006EUR$5,500USD£4,291GBP
- Report
- October 2023
- 85 Pages
United States
From €4414EUR$4,850USD£3,784GBP
- Report
- June 2022
- 207 Pages
Global
From €2389EUR$2,625USD£2,048GBP
€4778EUR$5,250USD£4,096GBP
- Report
- October 2021
- 110 Pages
Global
From €6234EUR$6,850USD£5,344GBP
- Report
- September 2023
- 98 Pages
Global
From €5415EUR$5,950USD£4,642GBP
- Report
- July 2022
- 165 Pages
Global
From €5415EUR$5,950USD£4,642GBP
- Report
- October 2021
- 210 Pages
Global
From €3413EUR$3,750USD£2,926GBP
- Report
- June 2023
- 150 Pages
Global
From €5415EUR$5,950USD£4,642GBP
- Report
- October 2022
- 68 Pages
Global
- Report
- February 2024
- 75 Pages
Global
From €4505EUR$4,950USD£3,862GBP
- Report
- November 2021
- 106 Pages
Global
From €4505EUR$4,950USD£3,862GBP
- Report
- April 2023
- 501 Pages
Global
From €3185EUR$3,500USD£2,731GBP
€4551EUR$5,000USD£3,901GBP

Car T therapies are a type of immunotherapy used to treat certain types of cancer. They involve the use of genetically modified T cells, which are a type of white blood cell, to recognize and attack cancer cells. The T cells are taken from the patient's blood, modified in a laboratory, and then infused back into the patient's body. This type of therapy has been used to treat certain types of leukemia and lymphoma, and is being studied for use in other types of cancer.
Car T therapies are a relatively new type of oncology drug, and the market is still in its early stages. However, the potential of this type of therapy has led to a surge of interest from pharmaceutical companies, investors, and researchers. Companies are investing in research and development to improve the safety and efficacy of these therapies, as well as to expand their use to other types of cancer.
Some of the companies in the Car T therapies market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Celgene. Show Less Read more